Multi-resistant Pseudomonas aeruginosa ST235 in cystic fibrosis

Paediatr Respir Rev. 2018 Jun:27:18-20. doi: 10.1016/j.prrv.2018.05.009. Epub 2018 May 18.

Abstract

Chronic Pseudomonas aeruginosa infection is associated with a decline in lung function and overall poorer prognosis in the cystic fibrosis population. Molecular typing of P. aeruginosa has identified multiple clonal strains with increased virulence and transmissibility. P. aeruginosa ST235 is an emerging clonal strain with multi-drug resistance and is associated with more virulent infections. Novel cephalosporins, which have recently been introduced to clinical practice, may have higher efficacy against multi-drug resistant bacteria.

Keywords: Ceftolozane–tazobactam; Cystic fibrosis; Molecular typing; Pseudomonas aeruginosa.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Cephalosporins / pharmacology*
  • Cystic Fibrosis* / complications
  • Cystic Fibrosis* / diagnosis
  • Cystic Fibrosis* / microbiology
  • Drug Resistance, Multiple, Bacterial*
  • Humans
  • Microbial Sensitivity Tests
  • Prognosis
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas Infections / etiology
  • Pseudomonas aeruginosa* / drug effects
  • Pseudomonas aeruginosa* / isolation & purification
  • Pseudomonas aeruginosa* / pathogenicity
  • Tazobactam / pharmacology*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • ceftolozane, tazobactam drug combination
  • Tazobactam